Stem cell committee urged to slow down
By Terri Somers,
San Diego Union-Tribune
| 01. 07. 2005
Ethics rules, transparency discussed at 2nd meeting
The committee that will dole out $3 billion in state grants for stem cell research heard yesterday from critics and some of its own members who said the group should slow down in its race to get money to scientists.
As the committee met for the second time, one of the overriding messages from the public and some of the committee members was to start by establishing standards for complicated and weighty issues such as how to reimburse taxpayers for their investment.
"No one wants results to come back faster than I do," said committee member Joan Samuelson, a former lawyer who has Parkinson's disease. "But some of these questions and issues are complicated. Some of the answers may take awhile."
The stem cell initiative that voters approved in November was set up to sidestep the slow crawl of bureaucracy and quickly get money to scientists looking for cures to diseases such as Parkinson's and Lou Gehrig's.
The committee's goal is to write the first check by the end of May, said Robert...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...